Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999535 | 0.81 | CREBBP (0.36) | ATMUSP30PARP1P2RX7GPR119 | |
| Indole SCHEMBL4409752 | 0.75 | IDO1 (0.36) | USP30PARP1 | |
| SCHEMBL739962 | 0.70 | MTNR1A (0.36) | TSHRSMN1; SMN2 | |
| SCHEMBL4260447 | 0.69 | HTR2A (0.38) | USP30USP2SMN1; SMN2GPR119 | |
| SCHEMBL29501163 | 0.69 | HCRTR2 (0.43) | ATMUSP30LMNASMN1; SMN2GPR119 | |
| SCHEMBL17958021 | 0.69 | HCRTR2 (0.43) | ATMUSP30LMNASMN1; SMN2GPR119 | |
| SCHEMBL1997467 | 0.69 | ALDH1A1 (0.38) | ALDH1A1TSHRLMNASMN1; SMN2MAPT | |
| SCHEMBL12553797 | 0.68 | ATM (0.44) | ATMALDH1A1USP2SMN1; SMN2MAPT | |
| SCHEMBL16004452 | 0.68 | USP30 (0.38) | OPRK1ATMUSP30ALDH1A1LMNA | |
| SCHEMBL17958028 | 0.67 | USP30 (0.40) | ATMUSP30GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960374-B2 | e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics | PROXIMAGEN LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| EP-2091953-A1 | 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS | BIOVITRUM AB (publ) (SE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080176829-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-07-24 | — | — | US | disclosed |
| WO-2008054288-A1 | 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS | BIOVITRUM AB (PUBL) (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176829-A1 | Compounds | HTR6, HTR1B, HTR1A | OPRK1 35/4885ATM 4008/4885USP30 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.